Shots:

• Polpharma has reported that its JV company- Bioeq has submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA. FYB201 was originally licensed from Formycon AG
• The launch of biosimilar ranibizumab may increase market competition- reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis
• Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases including wet AMD- DR- macular edemas and MCNV. If approved- Coherus will commercialize FYB201 in the US

  | Ref: Businesswire | Image: Businesswire